Physician profile
Kayla Cunningham
NPI 1609894534
$3,778.65
in general payments reported to CMS, 2019-2025
30 companies · $39.00 in 2025
The $39.00 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,764 · 2020: $825 · 2023: $15.64 · 2024: $134 · 2025: $39.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $189.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $709.24 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $532.31 | 2019-2020 | |
| Lilly USA, LLC | $315.81 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $255.31 | 2019-2020 | |
| Abbvie INC. | $229.96 | 2020-2025 | Synthroid |
| Insulet Corporation | $210.09 | 2019-2020 | |
| Abbott Laboratories | $179.19 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $154.34 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $151.97 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.32 | 2019-2020 | |
| Amgen INC. | $114.45 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $114.33 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $68.69 | 2019-2020 | |
| Medtronic Minimed, INC. | $61.63 | 2019 | |
| Corcept Therapeutics | $57.94 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $56.35 | 2019 | |
| Becton, Dickinson and Company | $51.12 | 2019 | |
| Amarin Pharma, INC. | $50.85 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $44.05 | 2019 | |
| Dexcom, INC. | $41.65 | 2019 | |
| Ibsa Pharma INC. | $38.75 | 2019-2020 | |
| Shire North American Group INC | $35.42 | 2019 | |
| Companion Medical, INC. | $33.53 | 2019-2020 | |
| Pfizer INC. | $24.56 | 2019 | |
| Valeritas, INC. | $21.80 | 2019 | |
| Senseonics, Incorporated | $20.00 | 2019 | |
| Mission Pharmacal Company | $19.45 | 2019 | |
| Radius Health, INC. | $15.69 | 2019 | |
| Aytu Biopharma, INC. | $15.09 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.